Kalobios Pharmaceuticals Inc., of South San Francisco, said the FDA cleared the investigational new drug application for its anti-granulocyte macrophage colony-stimulating factor, or GM-CSF, monoclonal antibody, KB003, enabling the company to initiate its open-label phase I study to evaluate safety, pharmacokinetics and clinical activity in previously treated patients with chronic myelomonocytic leukemia.